---
title: "Neurogene President, CFO Christine Mikail Cvijic sells 4,800 common shares for $166,407.28"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291596148.md"
description: "Neurogene President and CFO Christine Mikail Cvijic sold 4,800 common shares between July 1-2 at prices ranging from $34.06 to $35.23 per share, totaling $166,407.28. Following the transaction, her beneficial ownership decreased to 88,840 common shares."
datetime: "2026-07-02T22:43:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291596148.md)
  - [en](https://longbridge.com/en/news/291596148.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291596148.md)
---

# Neurogene President, CFO Christine Mikail Cvijic sells 4,800 common shares for $166,407.28

-   Neurogene President and CFO Christine Mikail Cvijic sold 4,800 common shares on July 1-2. \* Sales priced at USD 34.06 to USD 35.23 per share. \* Beneficial ownership fell to 88,840 common shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001543663-26-000015), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NGNE.US](https://longbridge.com/en/quote/NGNE.US.md)

## Related News & Research

- [Neurogene publishes corporate presentation highlighting NGN-401 gene therapy program for Rett syndrome](https://longbridge.com/en/news/295530994.md)
- [Neurogene President, CFO Christine Mikail Cvijic sells 4,800 shares for $173,468.40](https://longbridge.com/en/news/291993400.md)
- [Neurogene Q2 adjusted loss per share misses estimates on employee costs](https://longbridge.com/en/news/295530598.md)
- [Bridge to Life raises $110 million in Series C, debt financing led by Soleus with Lauxera backing](https://longbridge.com/en/news/295660425.md)
- [Kuya Silver posts Q2 loss as Bethania ramp-up lifts production costs above revenue, MD&A says](https://longbridge.com/en/news/295981430.md)